In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...

JACKSON, WY / ACCESS Newswire / April 1, 2025 / Labor Smart, Inc. (OTC PINK:LTNC), through its newest subsidiary Elevate ...

The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...